会议以 7 票同意，0 票弃权，0 票反对，审议通过了《关于注销参股公司暨 关联交易的议案》。关联董事陈卫武先生、曹保湖先生回避表决。 董事会 浙江仙琚制药股份有限公司 第八届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 《关于注销参股公司暨关联交易的公告》详见 2025 年 8 月 11 日的《证券时 报 》、《 中 国 证 券 报 》、《 上 海 证 券 报 》、《 证 券 日 报 》 和 巨 潮 资 讯 网 （www.cninfo.com.cn）。 证券代码：002332 证券简称：仙琚制药 公告编号：2025-031 特此公告。 浙江仙琚制药股份有限公司 浙江仙琚制药股份有限公司（以下简称"公司"）第八届董事会第十五次会 议通知已于 2025 年 8 月 4 日以电子邮件方式向公司全体董事发出，会议于 2025 年 8 月 10 日以通讯方式召开。本次会议应参加董事 9 名，实际参加董事 9 名， 会议由公司董事长张宇松先生召集并主持。本次会议的召集、召开符合《中华人 民共和国公司法》和《公司章程》的有关规定。全体与会董事 ...

Group 1 - The Shanghai Composite Index closed at 3635.13 points, above the annual line, with a slight decline of 0.12% [1] - The total trading volume of A-shares reached 17363.03 billion yuan [1] - A total of 35 A-shares have surpassed the annual line today, with notable stocks including Tianshan Co., Sany Heavy Energy, and Wantong Development, showing divergence rates of 7.78%, 7.56%, and 7.37% respectively [1] Group 2 - The stocks with the highest divergence rates from the annual line include: - Tianshan Co. (10.06% increase, 1.70% turnover rate, annual line at 5.38 yuan, latest price at 5.80 yuan, divergence rate 7.78%) [1] - Sany Heavy Energy (11.05% increase, 5.83% turnover rate, annual line at 25.88 yuan, latest price at 27.84 yuan, divergence rate 7.56%) [1] - Wantong Development (9.94% increase, 7.44% turnover rate, annual line at 7.11 yuan, latest price at 7.63 yuan, divergence rate 7.37%) [1] - Other stocks with smaller divergence rates that have just crossed the annual line include: - Yonggui Electric (3.82% increase, 10.44% turnover rate, annual line at 16.62 yuan, latest price at 17.12 yuan, divergence rate 3.02%) [1] - Landun Optoelectronics (6.61% increase, 15.78% turnover rate, annual line at 26.28 yuan, latest price at 26.92 yuan, divergence rate 2.42%) [1]

| 601139 | 深圳燃 | 0.92 | 0.30 | 6.57 | 6.61 | 0.63 | | --- | --- | --- | --- | --- | --- | --- | | | 气 | | | | | | | 002813 | 路畅科 | 1.36 | 2.69 | 24.37 | 24.52 | 0.63 | | | 技 | | | | | | | 000966 | 长源电 | 0.66 | 0.71 | 4.58 | 4.60 | 0.45 | | | 力 | | | | | | | 601158 | 重庆水 | 0.43 | 0.12 | 4.70 | 4.72 | 0.35 | | | 务 | | | | | | | 000875 | 吉电股 | 1.35 | 0.84 | 5.24 | 5.25 | 0.25 | | | 份 | | | | | | | 002032 | 苏泊尔 | 0.21 | 0.08 | 51.32 | 51.39 | 0.14 | | 002157 | 正邦科 | 0.70 | 0.38 | 2.87 | 2.87 | 0.12 | | | 技 | | ...

Market Overview - The Shanghai Composite Index is at 3636.69 points, slightly down by 0.08%, with a total trading volume of 802.9 billion yuan [1] - 21 A-shares have surpassed their annual line today, with notable stocks showing significant deviation rates [1] Stocks with Significant Deviation Rates - *ST Yitong has a deviation rate of 2.59%, with a price increase of 4.74% and a turnover rate of 2.93% [1] - Landun Optoelectronics shows a deviation rate of 1.97%, with a price increase of 6.14% and a turnover rate of 10.07% [1] - Guodian Power has a deviation rate of 1.53%, with a price increase of 1.52% and a turnover rate of 0.48% [1] Stocks with Smaller Deviation Rates - Pumen Technology and Jinlang Technology have just crossed the annual line with minor deviation rates of 0.06% and 0.13% respectively [2] - Longi Green Energy has a deviation rate of 0.20%, with a price increase of 0.25% [2]

Group 1 - Xianju Pharmaceutical Co., Ltd. has experienced a decline in stock price for seven consecutive trading days, with a cumulative drop of -5.94% [1] - The company, founded in 1972, aims to become one of the top ten steroid drug suppliers globally and focuses on the steroid hormone sector [1] - In the second quarter of this year, Xianju Pharmaceutical was added to the top ten shareholders of the Xinchuan He Feng three-year holding mixed fund, which has achieved a year-to-date return of 20.55% [1] Group 2 - Yang Shijin and Zhu Kefei are the current fund managers of the Xinchuan He Feng three-year holding mixed fund [4] - Zhu Kefei has been managing the fund since July 2, 2025, and has a tenure of 36 days with a return of 8.40% [3] - Xingsheng Global Fund Management Co., Ltd. was established in September 2003 and is co-owned by Xinyi Securities Co., Ltd. and Global Life Insurance International Company [3]

Group 1 - The company has submitted new products for review, including Estradiol Tablets, Betamethasone Mesylate Tablets, Tiotropium Bromide Inhalation Aerosol, and Progesterone Gel [2] - The development of innovative drugs generally goes through multiple stages, including target identification, compound discovery, preclinical research, and clinical trials [2]

Market Overview - As of 10:29 AM today, the Shanghai Composite Index stands at 3592.77 points, above the annual line, with a change of 0.30% [1] - The total trading volume of A-shares today is 857.68 billion yuan [1] Stocks Breaking Annual Line - A total of 27 A-shares have surpassed the annual line today, with notable stocks including: - Opcon Vision (300595) with a deviation rate of 9.58% - Mars (300894) with a deviation rate of 6.80% - Xianju Pharmaceutical (002332) with a deviation rate of 3.03% [1] Deviation Rate Rankings - The following stocks have the highest deviation rates from the annual line: - Opcon Vision: Today's increase of 12.38%, turnover rate of 3.83%, annual line at 16.41 yuan, latest price at 17.98 yuan [1] - Mars: Today's increase of 8.18%, turnover rate of 8.48%, annual line at 13.62 yuan, latest price at 14.55 yuan [1] - Xianju Pharmaceutical: Today's increase of 5.12%, turnover rate of 5.68%, annual line at 10.36 yuan, latest price at 10.67 yuan [1] Stocks with Smaller Deviation Rates - Stocks with smaller deviation rates that have just crossed the annual line include: - Beiqi Blue Valley (600733) with a deviation rate of 0.03% - Qianhe Flavor (603027) with a deviation rate of 0.05% - Luyang Energy (002088) with a deviation rate of 0.15% [2]

证券代码：002332 证券简称：仙琚制药 公告编号：2025-029 浙江仙琚制药股份有限公司 关于噻托溴铵吸入喷雾剂药品注册申请获得受理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江仙琚制药股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局下发的噻托溴铵吸入喷雾剂境内生产药品注册受理通知书，现将相关情况 公告如下： 品注册工作进入了审评阶段，公司将积极推进后续相关工作，如顺利通过审批将 丰富公司的产品线，有利于提升公司的市场竞争力。药品注册审批工作流程有一 定时间周期，存在不确定性因素，敬请广大投资者审慎决策，注意投资风险。 二、噻托溴铵吸入喷雾剂的相关情况 噻托溴铵吸入喷雾剂，规格为每瓶 60 喷，每喷递送剂量为噻托溴铵 2.5μg （按 C₁₉H₂₂NO₄S₂计），药液浓度含噻托溴铵 0.2262mg/ml（按 C₁₉H₂₂NO₄S₂计）， 参比制剂为原研药噻托溴铵吸入喷雾剂，持证商是 Boehringer Ingelheim International GmbH，商品名为 Spiriva® Respimat®。适应症为用于慢 ...

Group 1 - The company, Xianju Pharmaceutical (002332.SZ), has received a drug registration acceptance notice from the National Medical Products Administration for the production of Tiotropium Bromide Inhalation Spray [1] - The specifications of the Tiotropium Bromide Inhalation Spray include a delivery dose of 2.5μg per spray and a liquid concentration of 0.2262mg/ml [1] - The drug registration process has entered the review stage, and successful approval will enhance the company's product line and market competitiveness [1] Group 2 - The drug registration approval process has an uncertain timeline, which may affect investment decisions [1]

一、增资概述 浙江萃泽医药科技有限公司（以下简称"萃泽医药"）系浙江仙琚制药股份 有限公司（以下简称"公司"）的参股公司，公司持有其 37.3879%的股权。近 日，公司收到萃泽医药拟增加注册资本的通知，考虑到经营需求，萃泽医药注册 资本拟由 1529.0243 万元增资到 1618.0152 万元，拟增加注册资本 88.9909 万元， 增资价格为 37.0825 元/股。公司结合实际经营情况，拟放弃本次股权增资的优 先认缴出资权。 本次增资拟由以下 5 家投资方参与：仙居县海纳包装有限公司出资 1200 万 元人民币，王焕勇出资 900 万元人民币，王宝军出资 600 万元人民币，郑旭芬出 资 300 万元人民币，楼晓炯出资 300 万元人民币。拟参与增资的 5 家认购方以现 金出资合计 3300 万元人民币,认购萃泽医药的新增注册资本 88.9909 万元。本次 增资完成后，公司持有萃泽医药的股权比例由原来的 37.3879%降至 35.3316%。 本次放弃萃泽医药增资优先认购权事项已经公司第八届董事会第十四次会 议审议通过，根据《公司章程》、公司《投资管理制度》规定，本次放弃萃泽医 药增资优先认购权 ...